(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; Doconexent
cervonic acid, DHA
|Jmol 3D model||Interactive image|
|Molar mass||328.488 g/mol|
|Melting point||−44 °C (−47 °F; 229 K)|
|Boiling point||446.7 °C (836.1 °F; 719.8 K)|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Docosahexaenoic acid (DHA) is an omega-3 fatty acid that is a primary structural component of the human brain, cerebral cortex, skin, sperm, testicles and retina. It can be synthesized from alpha-linolenic acid or obtained directly from maternal milk (breast milk), fish oil or algae oil. DHA's structure is a carboxylic acid (-oic acid) with a 22-carbon chain (docosa- is Greek for 22) and six (hexa-) cis double bonds (-en-); with the first double bond located at the third carbon from the omega end. Its trivial name is cervonic acid, its systematic name is all-cis-docosa-4,7,10,13,16,19-hexa-enoic acid, and its shorthand name is 22:6(n-3) in the nomenclature of fatty acids.
Most of the DHA in fish and multi-cellular organisms with access to cold-water oceanic foods originates from photosynthetic and heterotrophic microalgae, and becomes increasingly concentrated in organisms the further they are up the food chain. DHA is also commercially manufactured from microalgae: Crypthecodinium cohnii and another of the genus Schizochytrium. DHA manufactured using microalgae is vegetarian.
Some animals with access to seafood make little DHA through metabolism, but obtain it in the diet. However, in strict herbivores, and carnivores that do not eat seafood, DHA is manufactured internally from α-linolenic acid, a shorter omega-3 fatty acid manufactured by plants (and also occurring in animal products as obtained from plants). Limited amounts of eicosapentaenoic and docosapentaenoic acids are possible products of α-linolenic acid metabolism in young women and men, and though DHA is difficult to detect above dietary background in males compared with females, this illustrates the importance of DHA production for the developing fetus and healthy breast milk. Rates of conversion are 15% higher for women, with those taking oral contraceptives demonstrating 10% higher DHA levels.
DHA is a major fatty acid in sperm, brain phospholipids and the retina. While the potential roles of DHA in the mechanisms of Alzheimer's disease are under active research, studies of fish oil supplements, which contain DHA, have failed to support claims of preventing cardiovascular diseases.
- 1 Central nervous system constituent
- 2 Metabolic synthesis
- 3 How it is metabolised
- 4 Potential health effects
- 5 Nutrition
- 6 Hypothesized role in human evolution
- 7 See also
- 8 References
- 9 External links
Central nervous system constituent
DHA is the most abundant omega-3 fatty acid in the brain and retina. DHA comprises 40% of the polyunsaturated fatty acids (PUFAs) in the brain and 60% of the PUFAs in the retina. Fifty percent of the weight of a neuron's plasma membrane is composed of DHA. DHA is richly supplied during breastfeeding, and DHA levels are high in breastmilk regardless of dietary choices.
DHA modulates the carrier-mediated transport of choline, glycine, and taurine, the function of delayed rectifier potassium channels, and the response of rhodopsin contained in the synaptic vesicles, among many other functions.
DHA deficiency is associated with cognitive decline. Phosphatidylserine (PS) controls apoptosis, and low DHA levels lower neural cell PS and increase neural cell death. DHA levels are reduced in the brain tissue of severely depressed patients.
In humans, DHA is either obtained from the diet or may be converted in small amounts from eicosapentaenoic acid (EPA, 20:5, ω-3) via docosapentaenoic acid (DPA, 22:5 ω-3) as an intermediate. This synthesis had been thought to occur through an elongation step followed by the action of Δ4-desaturase. It is now considered more likely that DHA is biosynthesized via a C24 intermediate followed by beta oxidation in peroxisomes. Thus, EPA is twice elongated, yielding 24:5 ω-3, then desaturated to 24:6 ω-3, then shortened to DHA (22:6 ω-3) via beta oxidation. This pathway is known as Sprecher's shunt.
How it is metabolised
|This section needs expansion. You can help by adding to it. (May 2016)|
Potential health effects
||This section needs more medical references for verification or relies too heavily on primary sources. (December 2013)|
Alzheimer's disease and decline of mental health
Preclinical studies indicate that DHA improves memory, can slow the progression of Alzheimer's disease neuropathology in mice, sparking interest in additional research. However, the first large-scale human trials showed that DHA did not slow decline of mental function in elderly people with mild to moderate Alzheimer's disease. These trials were part of a large US National Institutes of Health (NIH) intervention study to evaluate DHA in Alzheimer's disease.
Researchers from the National Institute on Aging supported Alzheimer's Disease Cooperative Study and conducted a clinical trial comparing DHA and placebo over 18 months in 402 people (average age=76) diagnosed with mild to moderate Alzheimer's disease. Treatment with DHA increased blood levels of DHA, and appeared to increase brain DHA levels, based on a measured increase of DHA in study participants' cerebrospinal fluid.
However, DHA treatment did not slow the rate of change on tests of mental function, global dementia severity status, activities of daily living, or behavioral symptoms in the study population as a whole. Treatment effects did not differ between the mild and moderate Alzheimer's patients, leading study authors to conclude that the results do not support the routine use of DHA for patients with Alzheimer's.
Animal studies in the various transgenic mouse models of Alzheimer's disease had linked dietary DHA to decreases in amyloid plaques and tau. Animal studies also showed, when DHA was combined with arachidonic acid (AA or ARA, also present in fish oil), plaque formation was greater with the arachidonic acid compared to DHA alone.
DHA deficiency is under study for its potential role in decline of mental function in healthy adults, indicated in a study from 2010 conducted at 19 U.S. clinical sites on 485 subjects aged 55 and older who met criteria for age-associated memory impairment. The study found algal DHA taken for six months decreased heart rate and improved memory and learning in healthy, older adults with mild memory complaints. These findings indicate the importance of early DHA intervention and provided a statistically significant benefit to cognitive function in individuals over 50 years of age.
Higher DHA levels in middle-aged adults is related to better performance on tests of nonverbal reasoning and mental flexibility, working memory, and vocabulary. DHA is the majority component of a Souvenaid, an oral supplement developed by MIT scientists that has been shown to modestly improve memory in subjects with early Alzheimer’s disease while showing insignificant benefits in other tests of cognitive function.
The use of DHA by persons with epilepsy could decrease the frequency of their seizures. Studies have shown that children with epilepsy had a major improvement, i.e. decrease in the frequency of their seizures, but another study showed mixed results with 57 adults taking DHA supplementation. The 57 subjects demonstrated a decreased frequency of seizures for the first six weeks of the study, but for some it was just a temporary improvement.
In mice, DHA was found to inhibit growth of human colon carcinoma cells, more than other omega-3 PUFAs. The cytotoxic effect of DHA was not caused by increased lipid peroxidation or any other oxidative damage, but rather a decrease in cell growth regulators. However, different cancer lines may handle PUFAs differently and display different sensitivities toward them.
DHA was shown to increase the efficacy of chemotherapy in prostate cancer cells in vitro, and a chemoprotective effect in a mouse model was reported. By contrast, one case-control study nested within a clinical trial originally designed to test the effect of finasteride on prostate cancer occurrence, the "Prostate Cancer Prevention Trial", found that DHA measured in blood serum was associated with an increase in high-grade prostate cancer risk. In addition to DHA's possible anticancer effect, it may also be used as a non-toxic adjuvant to increase the efficacy of chemotherapy.
Pregnancy and lactation
It has been recommended to eat foods which are high in omega-3 fatty acids for women who want to become pregnant or when nursing. DHA has recently[when?] gained attention as a supplement for pregnant women, noting studies of improved attention and visual acuity. Given the recently gained attention,[vague] the majority of pregnant women in the U.S. fail to get the recommended amount of DHA in their diets. A working group from the International Society for the Study of Fatty Acids and Lipids recommended 300 mg/day of DHA for pregnant and lactating women, whereas the average consumption was between 45 mg and 115 mg per day of the women in the study, similar to a Canadian study.
Although most studies demonstrate positive effects of dietary DHA on human health, some studies show little or no effect. For example, one study found that the use of DHA-rich fish oil capsules did not reduce postpartum depression in mothers or improve cognitive and language development in their offspring during early childhood. Another systematic review found that DHA had no significant benefits in improving visual field in individuals with retinitis pigmentosa.
Additional studies confirmed DHA benefits for other nervous system functions, cardiovascular health, and potentially other organs. In one study, men who took DHA supplements for 6–12 weeks decreased the concentrations of several inflammatory markers in their blood by approximately 20%. Higher intakes of DHA and EPA may reduce the risk of cardiovascular diseases. A new study found that higher intake of DHA was associated with slower rates of telomere shortening, which is a basic DNA-level marker of aging. Preliminary studies showed that a high intake of DHA was associated with reduced risk for developing Alzheimer's disease and Parkinson's disease consistent with DHA being the most abundant omega-3 fatty acid in the brain. Neuroprotective effects of dietary DHA have been described in animals models of Parkinson's disease. It is now considered so important to brain and eye development that DHA is included in most infant formulas. Lastly, in preliminary research, it was found that a diet rich in DHA might protect stroke victims from brain damage and disability and aid in a speedier recovery. Accordingly, dietary administration of DHA reduces stroke-induced neuroinflammation in animal models.
According to a new study, DHA is very likely important in the formation of the acrosome, an arc-like structure on the top of sperm, which is critical in fertilization because it houses a variety of enzymes that sperm use to penetrate an egg. Because humans and other mammals are able to make their own DHA from other fatty acids, DHA deficiency is not common. But, if that DHA-synthesizing enzyme is defective, it could lead to problems with infertility.
Ordinary types of cooked salmon contain 500–1500 mg DHA and 300–1000 mg EPA per 100 grams. Additional top fish sources of DHA include tuna, bluefish, mackerel, swordfish, anchovies, herring, sardines, and caviar. However, greater fish consumption's benefits in providing the recommended dosage of DHA are negated by the brain damage caused by toxic pollutants such as mercury.
Discovery of algae-based DHA
In the early 1980s, NASA sponsored scientific research in search of a plant-based food source that could generate oxygen and nutrition on long-duration space flights. The researchers discovered that certain species of marine algae produced rich nutrients. This research led to the development of an algae-based, vegetable-like oil that contains two essential polyunsaturated fatty acids, DHA and ARA (arachidonic acid), which can now be found in health supplements.
Use as a food additive
DHA is widely used as a food supplement. It was first used primarily in infant formulas. In 2004, the US Food and Drug Administration endorsed qualified health claims for DHA, and by 2007 DHA-fortified dairy items (milk, yogurt, cooking oil) started to appear in grocery stores.
DHA is believed to be helpful to people with a history of heart disease, for premature infants, and to support healthy brain development especially in young children along with supporting retinal development. Some manufactured DHA is a vegetarian product extracted from algae, and it competes on the market with fish oil that contains DHA and other omega-3s such as EPA. Both fish oil and DHA are odorless and tasteless after processing as a food additive.
Studies of vegetarians and vegans
Vegetarian diets typically contain limited amounts of DHA, and vegan diets typically contain no DHA. A supplemental DHA, available in algae-derived oils or capsules, has been shown to increase DHA levels. While there is little evidence of adverse health or cognitive effects due to DHA deficiency in adult vegetarians or vegans, fetal and breast milk levels remain a concern.
DHA and EPA in fish oils
Fish oil is widely sold in gelatin capsules containing a mixture of omega-3 fatty acids including EPA and smaller quantities of DHA. One study found that fish oil higher in EPA than DHA lowered inflammatory cytokines, such as IL-6 and IL-1β, associated with neurodegenerative and autoimmune diseases. They note the brain normally contains DHA, but not EPA, though both DHA and EPA plasma concentrations increased significantly for participants.
Oxidation levels of available fish oils
A study published in January 2015 revealed that "Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA". In another study "Oxidation of Marine Omega-3 Supplements and Human Health", the authors note: "It is currently impossible to determine how oxidation affects the efficacy or potential harms of marine oil. This makes interpretation of the clinical trial literature problematic. If the oxidative state of marine oils may affect efficacy or harm, then physicians should recommend, and consumers select, a supplement with the same oxidative state as the oils used in clinical trials that have shown benefit and safety."
Hypothesized role in human evolution
An abundance of DHA in seafood has been suggested as being helpful in the development of a large brain, though other researchers claim a terrestrial diet could also have provided the necessary DHA.
- Guesnet P, Alessandri JM; Alessandri (2011). "Docosahexaenoic acid (DHA) and the developing central nervous system (CNS) - Implications for dietary recommendations". Biochimie. 93 (1): 7–12. doi:10.1016/j.biochi.2010.05.005. PMID 20478353.
- The omega end is the one furthest from the carboxyl group.
- Martek Biosciences Corporation (5 April 2007). "History of Martek". Archived from the original on February 5, 2007. Retrieved March 10, 2007.
- Martek Biosciences Corporation (29 July 2008). "Martek Products". Archived from the original on June 12, 2008. Retrieved July 29, 2008.
- Burdge, G. C.; Wootton, S. A. (2002). "Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women". British Journal of Nutrition. 88 (4): 411–20. doi:10.1079/BJN2002689. PMID 12323090.
- Burdge, G. C.; Jones, A. E.; Wootton, S. A. (2002). "Eicosapentaenoic and docosapentaenoic acids are the principal products of α-linolenic acid metabolism in young men". British Journal of Nutrition. 88 (4): 355–363. doi:10.1079/BJN2002662. PMID 12323085.
- Malone, J. Patrick (2012). "The Systems Theory of Autistogenesis: Putting the Pieces Together". SAGE Open. 2 (2). doi:10.1177/2158244012444281.
- Giltay EJ, Gooren LJ, Toorians AW, Katan MB, Zock PL (2004). "Docosahexaenoic acid concentrations are higher in women than in men because of estrogenic effects". The American Journal of Clinical Nutrition. 80 (5): 1167–74. PMID 15531662.
- Cederholm T, Salem N Jr, Palmblad J (2013). "ω-3 fatty acids in the prevention of cognitive decline in humans". Adv Nutr. 4 (6): 672–6. doi:10.3945/an.113.004556. PMC . PMID 24228198.
- Zimmer, Carl (September 17, 2015). "Inuit Study Adds Twist to Omega-3 Fatty Acids' Health Story". New York Times. Retrieved October 11, 2015.
- O'Connor, Anahad (March 30, 2015). "Fish Oil Claims Not Supported by Research". New York Times. Retrieved October 11, 2015.
- Grey, Andrew; Bolland, Mark (March 2014). "Clinical Trial Evidence and Use of Fish Oil Supplements". JAMA Internal Medicine. 174 (3): 460–462. doi:10.1001/jamainternmed.2013.12765. Retrieved October 11, 2015.
- Meharban Singh (March 2005). "Essential Fatty Acids, DHA and the Human Brain from the Indian Journal of Pediatrics, Volume 72" (PDF). Retrieved October 8, 2007.
- Arthur A. Spector (1999). "Essentiality of Fatty Acids from Lipids, Vol. 34". Retrieved October 8, 2007.
- Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG.; Cui; Marcheselli; Bodker; Botkjaer; Gotlinger; Serhan; Bazan (October 2005). "A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease". J Clin Invest. 115 (10): 2774–83. doi:10.1172/JCI25420. PMC . PMID 16151530.
- Serhan CN, Gotlinger K, Hong S, Arita M; Gotlinger; Hong; Arita (2004). "Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis". Prostaglandins Other Lipid Mediat. 73 (3–4): 155–72. doi:10.1016/j.prostaglandins.2004.03.005. PMID 15290791.
- McNamara RK, Hahn CG, Jandacek R, et al. (2007). "Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder". Biol. Psychiatry. 62 (1): 17–24. doi:10.1016/j.biopsych.2006.08.026. PMID 17188654.
- McNamara, R. K.; Jandacek, R; Tso, P; Dwivedi, Y; Ren, X; Pandey, G. N. (2013). "Lower docosahexaenoic acid concentrations in the postmortem prefrontal cortex of adult depressed suicide victims compared with controls without cardiovascular disease". Journal of Psychiatric Research. 47 (9): 1187–91. doi:10.1016/j.jpsychires.2013.05.007. PMC . PMID 23759469.
- De Caterina, R; Basta, G (June 2001). "n-3 Fatty acids and the inflammatory response – biological background". European Heart Journal Supplements. 3 (Supplement D): D42–D49. doi:10.1016/S1520-765X(01)90118-X.
- A Voss; M Reinhart; S Sankarappa; H Sprecher (October 1991). "The metabolism of 7,10,13,16,19-docosapentaenoic acid to 4,7,10,13,16,19-docosahexaenoic acid in rat liver is independent of a 4-desaturase" (PDF). The Journal of Biological Chemistry. 266 (30): 19995–20000. PMID 1834642. Retrieved January 2, 2011.
- Westphal C, Konkel A, Schunck WH (Nov 2011). "CYP-eicosanoids--a new link between omega-3 fatty acids and cardiac disease?". Prostaglandins & Other Lipid Mediators. 96 (1-4): 99–108. doi:10.1016/j.prostaglandins.2011.09.001. PMID 21945326.
- Arsenault, Dany,; Carl Julien; et al. (2011). "DHA Improves Cognition and Prevents Dysfunction of Entorhinal Cortex Neurons in 3xTg-AD Mice". PLoS ONE. 6 (2): e17397. doi:10.1371/journal.pone.0017397. PMID 21383850.
- Calon, Frederic,; Giselle Lim; et al. (2004). "Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model". Neuron. 43 (5): 633–45. doi:10.1016/j.neuron.2004.08.013. PMID 15339646.
- "DHA Fights Alzheimer's Brain Plaques in Mice". US Department of Veterans Affairs.
- Lim, Giselle; Frederic Calon; et al. (March 23, 2005). "A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model" (PDF). The Journal of Neuroscience.
- Quinn JF, Raman R, Thomas RG, et al. (November 2010). "Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial". JAMA. 304 (17): 1903–11. doi:10.1001/jama.2010.1510. PMC . PMID 21045096.
- National Institute on Aging (July 16, 2007). "DHA Phase 3 trial in Alzheimer's disease". Retrieved August 10, 2007.
- Calon, Frederic; Greg Cole (2007). "Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: Evidence from animal studies". Prostaglandins Leukot Essent Fatty Acids. 77 (5–6): 287–93. doi:10.1016/j.plefa.2007.10.019. PMID 18037281.
- Joffre, Corinne; A Nadjar; et al. (2014). "n-3 LCPUFA improves cognition: the young, the old and the sick". Prostaglandins Leukot Essent Fatty Acids. 91 (1–2): 1–20. doi:10.1016/j.plefa.2014.05.001. PMID 24908517.
- Yurko-Mauro, K; McCarthy, D; Rom, D; Nelson, E. B.; Ryan, A. S.; Blackwell, A; Salem Jr, N; Stedman, M; Midas, Investigators (2010). "Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline". Alzheimer's & Dementia. 6 (6): 456–64. doi:10.1016/j.jalz.2010.01.013. PMID 20434961.
- Calon, F (2011). "Omega-3 polyunsaturated fatty acids in Alzheimer's disease: Key questions and partial answers". Current Alzheimer research. 8 (5): 470–8. doi:10.2174/156720511796391881. PMID 21605051.
- Matthew, Muldoon; Christopher M. Ryan; Lei Sheu; Jeffrey K. Yao; Sarah M. Conklin; Stephen B. Manuck (January 28, 2010). "Serum Phospholipid Docosahexaenonic Acid Is Associated with Cognitive Functioning during Middle Adulthood". Journal of Nutrition. 140 (4): 848–53. doi:10.3945/jn.109.119578. PMC . PMID 20181791.
- "MIT nutrient mixture improves memory in early Alzheimer's". CenterWatch News Online. 10 July 2012. Retrieved 14 June 2014.
- Scheltens, P; Twisk, J. W.; Blesa, R; Scarpini, E; von Arnim, C. A.; Bongers, A; Harrison, J; Swinkels, S. H.; Stam, C. J.; De Waal, H; Wurtman, R. J.; Wieggers, R. L.; Vellas, B; Kamphuis, P. J. (2012). "Efficacy of Souvenaid in mild Alzheimer's disease: Results from a randomized, controlled trial". Journal of Alzheimer's disease : JAD. 31 (1): 225–36. doi:10.3233/JAD-2012-121189 (inactive 2015-03-01). PMID 22766770.
- Yuen, A. W.; Sander, J. W.; Fluegel, D; Patsalos, P. N.; Bell, G. S.; Johnson, T; Koepp, M. J. (2005). "Omega-3 fatty acid supplementation in patients with chronic epilepsy: A randomized trial". Epilepsy & Behavior. 7 (2): 253–8. doi:10.1016/j.yebeh.2005.04.014. PMID 16006194.
- Kato T, Hancock RL, Mohammadpour H, McGregor B, Manalo P, Khaiboullina S, Hall MR, Pardini L, Pardini RS (2002). "Influence of omega-3 fatty acids on the growth of human colon carcinoma in nude mice". Cancer Letters. 187 (1–2): 169–77. doi:10.1016/S0304-3835(02)00432-9. PMID 12359365.
- Schønberg SA, Lundemo AG, Fladvad T, Holmgren K, Bremseth H, Nilsen A, Gederaas O, Tvedt KE, Egeberg KW, Krokan HE (2006). "Closely related colon cancer cell lines display different sensitivity to polyunsaturated fatty acids, accumulate different lipid classes and downregulate sterol regulatory element-binding protein 1". The FEBS Journal. 273 (12): 2749–65. doi:10.1111/j.1742-4658.2006.05292.x. PMID 16817902.
- Shaikh IAA, Brown I, Schofield AC, Wahle KWJ, Heys SD; Brown; Schofield; Wahle; Heys (November 2008). "Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway". Prostate. 68 (15): 1635–1646. doi:10.1002/pros.20830. PMID 18668525.
- Elmesery ME, Algayyar MM, Salem HA, Darweish MM, El-Mowafy AM; Al-Gayyar; Salem; Darweish; El-Mowafy (April 2009). "Chemopreventive and renal protective effects for docosahexaenoic acid (DHA): implications of CRP and lipid peroxides". Cell Div. 4 (1): 6. doi:10.1186/1747-1028-4-6. PMC . PMID 19341447.
- Brasky, T. M.; Till, C.; White, E.; Neuhouser, M. L.; Song, X.; Goodman, P.; Thompson, I. M.; King, I. B.; et al. (2011). "Serum Phospholipid Fatty Acids and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial". American Journal of Epidemiology. 173 (12): 1429–39. doi:10.1093/aje/kwr027. PMC . PMID 21518693.
- Siddiqui, R. A.; Harvey, K. A.; Xu, Z; Bammerlin, E. M.; Walker, C; Altenburg, J. D. (2011). "Docosahexaenoic acid: A natural powerful adjuvant that improves efficacy for anticancer treatment with no adverse effects". BioFactors. 37 (6): 399–412. doi:10.1002/biof.181. PMID 22038684.
- Harvard School Of Public Health. "Omega-3 Fatty Acids: An Essential Contribution". Retrieved 12 June 2015.
- Denomme J, Stark KD, Holub BJ (2005). "Directly quantitated dietary (n-3) fatty acid intakes of pregnant Canadian women are lower than current dietary recommendations". The Journal of Nutrition. 135 (2): 206–11. PMID 15671214.
- Imhoff-Kunsch B, Stein AD, Martorell R, Parra-Cabrera S, Romieu I, Ramakrishnan U (2011). "Prenatal docosahexaenoic acid supplementation and infant morbidity: randomized controlled trial". Pediatrics. 128 (3): e505–12. doi:10.1542/peds.2010-1386. PMC . PMID 21807696.
- Makrides M, Gibson RA, McPhee AJ, Yelland L, Quinlivan J, Ryan P (2010). "Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial". JAMA. 304 (15): 1675–83. doi:10.1001/jama.2010.1507. PMID 20959577.
- Rayapudi S, Schwartz SG, Wang X, Chavis P (2013). "Vitamin A and fish oils for retinitis pigmentosa". Cochrane Database Syst Rev. 12: CD008428. doi:10.1002/14651858.CD008428.pub2. PMID 24357340.
- Kelley, DS (Mar 2009). "DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men". J Nutr. 139 (3): 495–501. doi:10.3945/jn.108.100354.
- Pauwels, E. K.; Kostkiewicz, M (2008). "Fatty acid facts, Part III: Cardiovascular disease, or, a fish diet is not fishy". Drug news & perspectives. 21 (10): 552–61. doi:10.1358/dnp.2008.21.10.1314058 (inactive 2015-05-06). PMID 19221636.
- Farzaneh-Far, R; et al. (2010). "Association of Marine Omega-3 Fatty Acid Levels With Telomeric Aging in Patients With Coronary Heart Disease". JAMA. 303 (3): 250–257. doi:10.1001/jama.2009.2008.
- Samieri, C; Lorrain, S; Buaud, B; Vaysse, C; Berr, C; Peuchant, E; Cunnane, S. C.; Barberger-Gateau, P (2013). "Relationship between diet and plasma long-chain n-3 PUFAs in older people: Impact of apolipoprotein E genotype". The Journal of Lipid Research. 54 (9): 2559–67. doi:10.1194/jlr.P036475. PMC . PMID 23801662.
- Bazan, N. G.; Molina, M. F.; Gordon, W. C. (2011). "Docosahexaenoic acid signalolipidomics in nutrition: Significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases". Annual Review of Nutrition. 31: 321–51. doi:10.1146/annurev.nutr.012809.104635. PMC . PMID 21756134.
- Bousquet, M; Saint-Pierre, M; Julien, C; Salem Jr, N; Cicchetti, F; Calon, F (2008). "Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease". The FASEB Journal. 22 (4): 1213–25. doi:10.1096/fj.07-9677com. PMID 18032633.
- Aline Hittle. "DHA in Slowing the Progression of AD." Baylor College of Medicine. http://www.bcm.edu/neurology/alzheimers/index.cfm?pmid=16413
- "Kathleen Blanchard. "DHA in Fish Oil Could Protect from Stroke Disability." Louisiana State University.
- Lalancette-Hébert, M; Julien, C; Cordeau, P; Bohacek, I; Weng, Y. C.; Calon, F; Kriz, J (2011). "Accumulation of dietary docosahexaenoic acid in the brain attenuates acute immune response and development of postischemic neuronal damage". Stroke. 42 (10): 2903–9. doi:10.1161/STROKEAHA.111.620856. PMID 21852616.
- University of Illinois College of Agricultural, Consumer and Environmental Sciences (2012, January 18). Dietary DHA linked to male fertility
- Welsh J (2012). "Omega-3s vital for sperm health". LiveScience. Retrieved 27 March 2014.
- Jakobsen SE, Lie E (2013). "New treatment for psoriasis". ScienceNordic.
- "Appendix G2: Original Food Guide Pyramid Patterns and Description of USDA Analyses". Health.gov. Retrieved 15 September 2013.
- Zeilmaker, Marco J.; Hoekstra, Jeljer; van Eijkeren, Jan C. H.; de Jong, Nynke; Hart, Andy; Kennedy, Marc; Owen, Helen; Gunnlaugsdottir, Helga (2013-04-01). "Fish consumption during child bearing age: a quantitative risk-benefit analysis on neurodevelopment". Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association. 54: 30–34. doi:10.1016/j.fct.2011.10.068. ISSN 1873-6351.
- Jones, John. "Nutritional Products from Space Research". May 1st, 2001. NASA.
- "Algae Oil Supplements and How They Help". Oily Oily. Retrieved 15 September 2013.
- "FDA: Why is there interest in adding DHA and ARA to infant formulas?". US Food & Drug Administration. Retrieved July 2002. Check date values in:
- "FDA Announces Qualified Health Claims for Omega-3 Fatty Acids". US Food & Drug Administration.
- Rivlin, Gary (2007-01-14). "Magical or Overrated? A Food Additive in a Swirl". The New York Times. Retrieved 2007-01-15.
- Sanders, Thomas A.B. (August–September 2009). "DHA status of vegetarians". Prostaglandins, Leukotrienes, and Essential Fatty Acids. International Society for the Study of Fatty Acids and Lipids. 81 (2–3): 137–141. doi:10.1016/j.plefa.2009.05.013. ISSN 0952-3278. PMID 19500961.
- Vedin I, et al. (1 June 2008). "Effects of docosahexaenoic acid–rich n–3 fatty acid supplementation on cytokine release". Am J Clin Nutr. 87 (6): 1616–1622. PMID 18541548.
- Benjamin B Albert (21 January 2015). "Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA release". Nature, Scientific Reports. 5: 7928. doi:10.1038/srep07928.
- Albert, Benjamin B.; Cameron-Smith, David; Hofman, Paul L.; Cutfield, Wayne S. (2013). "Oxidation of Marine Omega-3 Supplements and Human Health". BioMed Research International. 2013: 1–8. doi:10.1155/2013/464921. PMID 23738326.
- Crawford, M; et al. (2000). "Evidence for the unique function of docosahexaenoic acid (DHA) during the evolution of the modern hominid brain". Lipids. 34 (S1): S39–S47. doi:10.1007/BF02562227. PMID 10419087.
- Carlson BA, Kingston JD; Kingston (2007). "Docosahexaenoic acid biosynthesis and dietary contingency: Encephalization without aquatic constraint". Am. J. Hum. Biol. 19 (4): 585–8. doi:10.1002/ajhb.20683. PMID 17546613.